Who
Julie Cooke
Chief Human Resources Officer
Company insider
Files Form 4 as: Chief Human Resources Officer, Neurocrine Biosciences.
In numbers
- Trades disclosed
- 138
- Buys
- 0
- Sells
- 37
- Bought
- $0
- Sold
- $26.3M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 2 Oct 2019
- Last trade
- 11 Sep 2026
- Last filed
- 15 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code A | —3,587 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code F | $302K1,936 at $156.22 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code A | —3,587 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code F | $302K1,936 at $156.22 | filing |
| 2 Jun 2026filed 4 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | $2.0M24,965 at $81.49 | filing |
| 2 Jun 2026filed 4 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $2.2M14,214 at $154.83 | filing |
| 2 Jun 2026filed 4 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $850K5,466 at $155.46 | filing |
| 2 Jun 2026filed 4 Jun 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —24,965 at $0.00 | filing |
| 2 Jun 2026filed 4 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $661K4,216 at $156.77 | filing |
| 2 Jun 2026filed 4 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $1.5M9,521 at $157.62 | filing |
| 2 Jun 2026filed 4 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $558K3,520 at $158.59 | filing |
| 2 Jun 2026filed 4 Jun 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —24,965 at $0.00 | filing |
| 2 Jun 2026filed 4 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | $2.0M24,965 at $81.49 | filing |
| 2 Jun 2026filed 4 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $2.2M14,214 at $154.83 | filing |
| 2 Jun 2026filed 4 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $850K5,466 at $155.46 | filing |
| 2 Jun 2026filed 4 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $661K4,216 at $156.77 | filing |
| 2 Jun 2026filed 4 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $1.5M9,521 at $157.62 | filing |
| 2 Jun 2026filed 4 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $558K3,520 at $158.59 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,401 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,510 at $0.00 | filing |
News
Contrasting Neurocrine Biosciences (NASDAQ:NBIX) and Perrigo (NYSE:PRGO)NBIX · dailypolitical.com · 10 Oct 2026
0 headlines in the last 90 days name Julie Cooke; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.